SECURITIES AND EXCHANGE COMMISSION
               WASHINGTON, DC  20549

                    FORM 12b-25
                    Commission File Number 0-18170

            NOTIFICATION OF LATE FILING

   (Check One): [X] Form 10-K and Form 10-KSB [ ]
Form 11-K [ ] Form 20-F [ ] Form 10-Q and Form 10-
QSB
   [ ] Form N-SAR

For Period Ended:                                 December
26, 1999
[ ] Transition Report on Form 10-K         [ ]
Transition Report on Form 10-Q
[ ] Transition Report on Form 20-F         [ ]
Transition Report on Form N-SAR
[ ] Transition Report on Form 11-K
For Transition Period Ended:


Read attached instruction sheet before preparing form.
Please print or type.
   Nothing in this form shall be construed to imply that
the Commission has verified any information contained
herein.

   If the notification relates to a portion of the filing
checked above, identify the Item(s) to which the
notification relates:

PART I - REGISTRANT INFORMATION
                                      Cryomedical Sciences,
Inc.
Full name of registrant

Former name if applicable
                                        1300 Piccard Drive

Address of principal executive office (Street and number)
                                        Rockville, Maryland
20850
City, State and Zip Code

PART II - RULES 12B-25(b) AND (c)

   If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks
relief pursuant to Rule 12b-25(b), the following should
be completed.  (Check appropriate box.)

       (a) The reasons described in reasonable detail in
       Part III of this form could not be eliminated
       without unreasonable effort or expense;

       (b) The subject annual report, semi-annual
report, transition report on Form 10-K, Form 20-F, 11-
K or Form -[X]               N-SAR, or portion
thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date;            or
the subject quarterly report or transition report on Form
10-Q, or portion thereof will be filed on or before
       the fifth calendar day following the prescribed
due date; and

       (c) The account's statement or other exhibit
       required by Rule 12b-25(c) has been attached if
       applicable.

PART III - NARRATIVE

    State below in reasonable detail the reasons why
Forms 10-K, 20-F, 11-K, 10-Q, N-SAR or the transition
report portion thereof could not be filed within the
prescribed time period.  (Attach extra sheets if needed.)

              The registrant's annual report on
       Form 10-KSB is being filed late due to
       delays associated with the Company's
       upcoming move to new facilities, and
       delays by the Company in providing the
       documentation necessary for completing
       the audit for the fiscal year ended
       December 26, 1999.


PART IV - OTHER INFORMATION

    (1)  Name and telephone number of person to
contact in regard to this notification

              Richard  J. Reinhart
        (301)      417-7070
              (Name)
(Area code)   (Telephone number)

    (2)  Have all other periodic reports required under
Section 13 or 15(d) of the Securities exchange Act of
1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter
period that the registrant was required to file such
report(s) been filed?  If the answer is no, identify
report(s).

                                    [X] Yes [ ] No

    (3)  Is it anticipated that any significant change in
results of operations from the corresponding period for
the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion
thereof?


                                    [ ] Yes [X] No

    If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if
appropriate, state the reasons why a reasonable estimate
of the results cannot be made.









                      Cryomedical Sciences, Inc.

   (Name of registrant as specified in charter)

has caused this notification to be signed on its behalf by
the undersigned thereunto duly authorized.

Date  March 24, 1999           By /s/ Richard J.
Reinhart
Dr. Richard Reinhart, Ph.D., President and Chief
Executive Officer

       Instruction.  The form may be signed by an
    executive officer of the registrant or by any
    other duly authorized representative.  The name
    and title of the person signing the form shall be
    typed or printed beneath the signature.  If the
    statement is signed on behalf of the registrant
    by an authorized representative (other than an
    executive officer), evidence of the
    representative's authority to sign on behalf of
    the registrant shall be filed with the form.

                     ATTENTION

    Intentional misstatements or omissions of fact
constitute Federal criminal violations (see 18 U.S.C.
1001).